ARWR and MDGL Related Headlines

Go Back

May 5, 2026 08:03AM Arrowhead licenses liver disease drug to Madrigal for $25 million upfront

May 5, 2026 08:00AM Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

ARWR and MDGL Related Press Releases

Go Back

May 5, 2026 08:00AM Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

ARWR and MDGL Related SEC Filings

Go Back